Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Investigation of the LSD1 Inhibitor Iadademstat (ORY-1001) in Combination With Azacitidine and Venetoclax in Newly Diagnosed Acute-myeloid-leukaemia

Next Previous
Search
Trial Profile

A Phase Ib Investigation of the LSD1 Inhibitor Iadademstat (ORY-1001) in Combination With Azacitidine and Venetoclax in Newly Diagnosed Acute-myeloid-leukaemia

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iadademstat (Primary) ; Azacitidine; Venetoclax
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions

    • Most Recent Events

    • 09 Sep 2024 According to an Oryzon media release, the company announced that the first patient has been dosed.
    • 31 Jul 2024 According to an Oryzon media release, this Phase Ib dose-finding study is now open for recruitment, and is expected to begin enrolling patients in 3Q2024.
    • 19 Jul 2024 Planned initiation date changed from 30 Jun 2024 to 16 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top